LAUSR

Ankylosing spondylitis (AS) is a chronic autoimmune arthritis disease with a genetic background, affecting the skeletal axis, sacroiliac, and peripheral joints. Nonsteroidal anti‐inflammatory drugs (NSAIDs) are the first‐line treatment for AS to alleviate the inflammation and pain. Despite the beneficial effect, their use is accompanied by a wide variety of possible side effects in the gastrointestinal and kidneys. The α‐l‐guluronic acid (G2013) is a new nonsteroidal anti‐inflammatory patented (PCT/EP2017/067920) drug, which has shown its anti‐inflammatory properties in the previous investigations. The present study revealed the oral administration effect of G2013 on COX‐1 and COX‐2 gene expression in AS patients. The blood samples of twelve 18–45 years old patients suffering AS and BASDAI >4, and BASFI >4, before and after 12 weeks of treatment with G2013 and 12 blood samples of healthy volunteers were collected and the effect of G2013 on the gene expression of COX‐1 and COX‐2 enzymes were assessed by Real‐Time PCR. The results indicate that G2013 is able to reduce the gene expression level of COX‐1 and COX‐2 enzymes in treated AS patients compared to healthy control. Statistically significant differences were not observed between the treatment and the healthy control groups. According to the findings, G2013 might be categorized and introduced as a novel NSAID for the treatment of AS.